ID

34734

Descripción

Study ID: 101998 Clinical Study ID: 101998 Study Title: A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier Sponsor GlaxoSmithKline Collaborators N/A Phase Phase 3 Study Recruitment Status Completed Generic Name sumatriptan Trade Name Imitrex ,Imiject ,Imigran Study Indication Migraine Disorders The purpose of this form is to document the subjects intake of the investigational product and the status of treatment blind. It should be filled out at the final visit.

Palabras clave

Versiones (2)

1. 23/1/19 23/1/19 -
2. 25/1/19 25/1/19 - Sarah Riepenhausen

Titular de derechos de autor

GlaxoSmithKline

Subido en

25 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia